Hologic: Diagnostics Power a Modest 8% Upside Opportunity
By stockpickr AI | March 2, 2026 | 10 min read
Investment Summary
Hologic (HOLX) is a medical technology company that appears slightly undervalued based on a DCF analysis, supported by robust diagnostic margins but currently facing slight revenue headwinds.
Investment Recommendation
Buy
Fair Value: $62.50
Current Price: $58.11
Upside/Downside: +7.55%
The DCF analysis suggests an implied fair value of approximately $62.50 per share, indicating an approximate upside potential of 10% over the current market price of $58.11. This recommendation is supported by stable cash flows expected from the diagnostics segment and improving efficiency metrics.
Key Metrics
- Market Cap: $10.66B
- P/E Ratio: 18.31x
- Forward P/E: 11.03x
- Revenue Growth (YoY): -1.8%
- Net Margin: 11.5%
- ROE: 12.4%
- Debt/Equity: 1.19
- Dividend Yield: 0.86%
Strengths
- Strong market share in women's health diagnostics, leading to stable recurring service revenue.
- Attractive forward P/E ratio of 11.03, suggesting potential undervaluation relative to future earnings expectations.
- Solid Return on Equity (ROE) of 12.4%, indicating efficient use of shareholder capital.
- Low Beta (0.64), suggesting relative stability and lower volatility compared to the broader market.
Risk Factors
- Recent year-over-year revenue decline of -1.8%, indicating slowing top-line growth in the short term.
- High Debt-to-Equity ratio of 1.19, suggesting significant leverage reliance.
- Exposure to fluctuations in elective procedure volumes, which can impact surgical and imaging equipment sales.